Novavax
WHO confirmed a Phase III study conducted in the U.S. and Mexico during a period in which multiple variants (Alpha, Beta, and Delta) were in circulation found the Novavax vaccine efficacy against mild, moderate, or severe COVID-19 was 90%.
The company is also developing a COVID-19-Influenza Combination (CIC), with CEO Stanley C. Erck saying, “We believe that like influenza, COVID-19 will also be seasonal moving forward, and that there is room in the market for new alternatives to provide better protection against the impact of influenza, particularly in older adults, and to explore the potential to combine this with protection from COVID.”
